Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Journal"

ASSESSMENT OF THE ADHERENCE TO THERAPY IN PATIENTS WITH THE FIRST-EPISODE SCHIZOPHRENIA

N.N.Petrova, K.A. Tsyrenova

Saint-Petersburg State University, Saint-Petersburg, Russia

SUMMARY
First episode of schizophrenia is characterized by specific features of a response to the therapy and by adherence problems. The objectives of this study were to assess adherence to therapy in patients with the first episode of schizophrenia at the stage of remission, depending on the nature of the antipsychotic therapy. Material and methods. 50 patients diagnosed with F20.0 "Paranoid schizophrenia" with episodic course and progressive defect (26 women and 24 men, age 26.31 ± 5.50 years) were examined on the stage of remission. They were divided into two groups depending on the nature of antipsychotic therapy: 22 patients receiving first generation antipsychotics (FGA) and 28 patients receiving second generation antipsychotics (SGA) monotherapy.The validated Russian-language version of the PANSS scale, the adverse event assessment scale of the therapy (UKU), the compliance assessment scale (DAI), the social and personal functioning scale (PSP) were used. The criteria for inclusion of patients were the duration of the disease not more than 5 years, the number of psychotic episodes not more than 3, the stage of remission.

Results. Patients receiving FGA had more side effects, both mental, neurological and autonomic. The severity of side effects in patients receiving FGA was greater compared with patients receiving SGA as a whole (6.23 ± 1.5 and 2.01 ± 1.5 points, respectively, p< 0.05), and in terms of mental effects (3.43 ± 0.7 and 1.11 ± 0.7 points, respectively, p< 0.05). Attentional disorders were more pronounced in patients treated with FGA (0.81 ± 0.1 and 0.31 ± 0.1 points, p< 0.05), as well as fatigue (0.72 ± 0.1 and 0, 1 ± 0.1 points, respectively, p< 0.05), EPS (p< 0.05), and constipation (0.5 ± 0.1 and 0.1 ± 0.1 points, respectively, p< 0.05). Patients who received SGA had a tendency to gain weight (0.4 ± 0.1 and 0.2 ± 0.1 points). The severity of side effects of antipsychotic therapy correlated with the level of compliance (r = –0.53; p<0.05). Compliance was higher in patients receiving SGA.

Conclusion. The present naturalistic study showed that the tolerability of antipsychotic therapy was significantly higher in patients with the first episode of schizophrenia who received SGA, with the exception of an increase in body weight. They had a higher level of compliance as compared with patients treated with FGA.

Contact: 07 petrova_nn@mail.ru

References: 

1. ZajcevaYu.S.,Korsakova N.K. Dinamikanejrokognitivnogodeficita u pacientov s razlichnojstepen`yuprogredientnostishizofreniipripervy`xpristupaxi v techenie 5-letnego katamneza // Social`nayaiklinicheskayapsixiatriya. – 2008. – № 2. – S. 15–25.
2. Mosolov S.N., Czukarzi E`.E`., Kapiletti S.G. Antipsixoticheskayafarmakoterapiyashizofrenii: otnauchny`xdanny`x k klinicheskimrekomendaciyam // Biologicheskiemetody` terapiipsixicheskixrasstrojstv. Dokazatel`nayamedicina – klinicheskojpraktike. – M.: Social`no-politicheskayamy`sl`, 2012. – S. 11–61.
3. Robinson D., Woerner M.G., Alvir J.M. et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder // Arch Gen Psychiatr. –1999. – Vol. 56. – P. 241–247.
4. T.S.S.R. Group. The Scotish first episode schizophrenia study VIII. Five-year follow-up: clinical and psychosocial findings // Brit J Psychiatr. – 1992. – Vol. 161. – P. 508–520.
5. Thieda P., Beard S., Richter A. Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia // Psychiatr Serv. – 2003. – Vol. 54, No. 4. – P. 508–516.
6. Weiden P.J., Olfson M. Cost of relapse in schizophrenia // Schizophr Bull. – 1995. – Vol. 21, No. 3. – P. 419–429.
7. Robinson D.G., Woerner M.G., Alvir J.M. et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder // Schizophr Res. – 2002. – Vol. 57, No. 2–3. – P. 209–219.
8. Verdoux H., Lengronne J., Liraud F. et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first admitted subjects // ActaPsychiatr Scand. – 2000. – Vol. 102, No. 3. – P. 203–210.
9. Coldham E.L., Addington J., Addington D. Medication adherence of individuals with a first episode of psychosis // ActaPsychiatr Belg. – 2011. – Vol. 111, No. 1. – P. 286–290.
10. Avedisova A.S. Otnonkomplajensa k otkazuotpsixofarmakoterapii // Psixiatriyaipsixofarmakoterapiya. – 2005. – № 6. – S. 316–324.
11. Lutova N.B. Komplajens v psixiatriiipodxody` k ego uluchsheniyu // Rossijskijpsixiatricheskijzhurnal. – 2012. – № 2. – S. 20–25.
12. Neznanov N.G., Vid V.D. Problemakomplajensa v klinicheskojpsixiatrii // Psixiatriyaipsixofarmakoterapiya. – 2004. – T. 6, № 4. – S. 213–214.
13. Juckel G., de Bartolomeis A., Gorwood P. et al. Towards a framework for treatment effectiveness in schizophrenia // Neuropsychiatric Disease and Treatment. – 2014. – Vol. 10. – P. 1867–1878.
14. GurovichI.Ya.,Shmukler A.B Pervy`jpsixoticheskije`pizod (problemy` ipsixiatricheskayapomoshh`). – M.: Medpraktika, 2010. – 543 s.
15. Mosolov S.N. Shkaly` psixometricheskojocenkisimptomatikishizofreniiikoncepciyapozitivny`xinegativny`xrasstrojstv. – M.: Novy`jczvet, 2001. – 238 s.
16. Mosolov S.N., Potapov A.V., Czukarzi E`.E`. Standartizirovanny`ekliniko-funkcional`ny`ekriteriiterapevticheskojremissiiprishizofrenii: metodich. ukazaniya. – M.: FGBU «NMICzPNim. V.P. Serbskogo» MZ RF, 2017. – 73 s.
17. Lindstrom E., Lewander T., Malm U., Malt U.F., Lublin H., Ahlfors U.G. Patient rated versus clinician rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of UKU Side Effect Rating Scale (UKU-SERS-Pat) // Nord J Psychiatry. – 2001. – Vol. 44. – P. 5–69.
18. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity // Psychol Med. – 1983. – Vol. 13. – P. 177–183.
19. Morosini P.L., Magliano L., Brambilla L. et al. Development, reliability and acceptability of a new version of the DSM–IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning // ActaPsychiatricaScandinavica. – 2000. – Vol. 101. – P. 323–329.
20. Mutsatsa S. et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study // ActaPsychiatricaScandinavica. – 2003. – No. 6. – R. 439–446.
21. Perkins D. Predictors of noncompliance in patients with schizophrenia // J Clin Psychiatry. – 2002. – Vol. 63, No. 12. – R. 1121–1128.
22. Morozova M.A. Rubashkina V.V., Burminskij D.S. i dr. Dinamikakomplaentnostibol`ny`xshizofreniej v xodedlitel`nogosravnitel`nogopsixofarmakologicheskogoissledovaniyatipichny`xiatipichny`xantipsixotikov // Psixiatriya. – 2007. – № 3. – S. 15–25.
23. Tek C., Kucukgoncu S., Guloksuz S., Woods S.W., Srihari V.H., Annamalai A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications // Early Intervention in Psychiatry. – 2015. – Article first published online: DOI: 10.1111/eip.12251
24. Xasan A., Falkai P., Vobrok T. i dr. RukovodstvopobiologicheskojterapiishizofreniiVsemirnojfederaciiobshhestvbiologicheskojterapii (WFSBP). Ch. 1. Obnovlennayaredakciya 2012 g. poterapiiostrogopristupashizofreniiiterapevticheskirezistentny`xsluchaev // Sovremennayaterapiyapsixicheskixrasstrojstv. – 2013. – № 1. – S. 3–40.
25. Angermeyer M. et al. Neuroleptics and quality of life. A patient survey // PsychiatrPrax. – 2000. – No. 2. – R. 64–68.
26. Petrova N.N., Dorofejkova M.V., Voinkova E.E. Kognitivny`enarusheniya u bol`ny`xshizofreniejnarazny`xe`tapaxtecheniyazabolevaniya // Zhurnalnevrologiiipsixiatriiimeni C.C. Korsakova. – 2016. – T. 116, № 4. – S. 10–15.
27. Petrova N.N., Voinkova E.E. Sravnitel`nayaocenkae`ffektivnostipsixofarmakoterapiibol`ny`x s pervy`mpsixoticheskime`pizodom // Ucheny`ezapiski Sankt-Peterburgskogogosudarstvennogomedicinskogouniversitetaimeniakademika I.P. Pavlova. – 2015. – T. 22, № 3. – S. 48–50. https://doi.org/10.24884/1607-4181-2015-22-3-48-50